Capsid Protein Ratio (VP1/VP2/VP3)

The Adeno-Associated Virus (AAV) capsid is a protein shell composed of 60 subunits made from three distinct structural viral proteins: VP1, VP2, and VP3. These proteins assemble in a specific stoichiometric ratio, which is critical for the vector's structural integrity and biological function. The Capsid Protein Ratio is a CQA that supports the identity and purity of the viral particle by verifying this subunit composition. It is a key indicator of proper viral assembly and manufacturing consistency.

Complete Denaturation: The methods require the complete disruption of the highly stable AAV capsid into its individual protein subunits. Incomplete denaturation can lead to inaccurate and highly variable results.

Resolution: The VP proteins are very similar in size and properties, which presents an analytical challenge that requires high-resolution methods. Modern platforms, particularly Capillary Electrophoresis (CE-SDS) systems like the ProteinSimple Maurice or PerkinElmer LabChip, have proven to be highly effective and are now the industry standard for achieving the necessary baseline separation and quantitation.

• Early Phase (Phase 1-2): The primary focus is on characterization to establish the expected ratio for the product and to develop a suitable, qualified analytical method. A specification may be in place with a relatively wide acceptance range.
• Late Phase & Commercial (Phase 3/BLA): A fully validated release assay with a tight, justified specification is required. The capsid ratio is a key attribute used to demonstrate manufacturing consistency between batches and after any process changes.

• Patient Risk: An incorrect VP ratio indicates improperly formed viral particles. Specifically, a deficient amount of the VP1 and VP2 proteins, which are critical for viral trafficking and endosomal escape, can lead to a less infectious vector. This results in a direct loss of Potency and a risk of reduced or no efficacy for the patient.
• Manufacturing Risk: A shift in the VP ratio is a sensitive indicator of a problem in the upstream manufacturing process, such as an incorrect ratio of plasmids during transfection or a drift in the host cell's expression machinery. This can lead to batch rejection.

• Potency/Biological Activity: The capsid protein ratio can strongly influence infectivity and functional potency, particularly when VP1 or VP2 are significantly depleted.
• Purity & Impurities: A batch with an incorrect capsid ratio can be considered to have an excess of "product-related impurities" in the form of improperly formed or non-functional particles.
• Identity: The specific 1:1:10-like ratio is a characteristic fingerprint of a properly assembled AAV capsid, contributing to its identity profile.

The accepted industry standard is that the capsid protein ratio must be measured and controlled. While the theoretical 1:1:10 ratio serves as a benchmark, it is widely understood that different manufacturing systems and AAV serotypes can produce slight, yet consistent, variations. The key is not necessarily to achieve the exact theoretical ratio, but to demonstrate that the ratio produced by your process is consistent over time and is representative of a fully potent and stable product.

• Product Characterization (ICH Q6B): The principles of this guideline require the characterization of the product's protein composition, which for a multi-subunit particle like an AAV capsid, includes the identity and ratio of its constituent proteins.
• Gene Therapy Guidance (FDA/EMA): Specific regulatory guidance for gene therapies emphasizes the need for extensive characterization of the vector. This includes providing data on the protein components of the capsid to ensure identity, purity, and consistency.